"Apolipoprotein A-I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. This protein serves as an acceptor for CHOLESTEROL released from cells thus promoting efflux of cholesterol to HDL then to the LIVER for excretion from the body (reverse cholesterol transport). It also acts as a cofactor for LECITHIN CHOLESTEROL ACYLTRANSFERASE that forms CHOLESTEROL ESTERS on the HDL particles. Mutations of this gene APOA1 cause HDL deficiency, such as in FAMILIAL ALPHA LIPOPROTEIN DEFICIENCY DISEASE and in some patients with TANGIER DISEASE.
| Descriptor ID |
D016632
|
| MeSH Number(s) |
D10.532.091.200.100 D12.776.070.400.200.100 D12.776.521.120.200.100
|
| Concept/Terms |
Apolipoprotein A-I- Apolipoprotein A-I
- Apolipoprotein A I
- Apo A-I
- Apo A1
- Apolipoprotein AI
- ApoA-1
- ApoA-I
- Apolipoprotein A-1
- Apolipoprotein A 1
- Apolipoprotein A1
- Apo A-1
- Apo AI
Pro-Apolipoprotein A-I- Pro-Apolipoprotein A-I
- Pro Apolipoprotein A I
- Pro-Apo A-I
- Pro Apo A I
- Proapolipoprotein AI
- Apolipoprotein AI Propeptide
|
Below are MeSH descriptors whose meaning is more general than "Apolipoprotein A-I".
Below are MeSH descriptors whose meaning is more specific than "Apolipoprotein A-I".
This graph shows the total number of publications written about "Apolipoprotein A-I" by people in this website by year, and whether "Apolipoprotein A-I" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 4 | 6 |
| 2004 | 2 | 1 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 4 | 0 | 4 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 3 | 5 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 4 | 6 |
| 2012 | 2 | 1 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Apolipoprotein A-I" by people in Profiles.
-
Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate. PLoS One. 2012; 7(10):e48663.
-
A proteoliposome containing apolipoprotein A-I mutant (V156K) enhances rapid tumor regression activity of human origin oncolytic adenovirus in tumor-bearing zebrafish and mice. Mol Cells. 2012 Aug; 34(2):143-8.
-
Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. Br J Cancer. 2012 Feb 28; 106(5):955-61.
-
Identification of an amino acid residue in ATP-binding cassette transport G1 critical for mediating cholesterol efflux. Biochim Biophys Acta. 2012 Mar; 1821(3):552-9.
-
Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol. 2011 Sep; 122(3):548-53.
-
Enhanced delivery of adenovirus, using proteoliposomes containing wildtype or V156K apolipoprotein A-I and dimyristoylphosphatidylcholine. Hum Gene Ther. 2010 May; 21(5):579-87.
-
Disruption of human plasma high-density lipoproteins by streptococcal serum opacity factor requires labile apolipoprotein A-I. Biochemistry. 2009 Feb 24; 48(7):1481-7.
-
High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy. Clin Chem. 2007 Mar; 53(3):525-8.
-
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004 Aug 15; 64(16):5882-90.
-
Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci. 1994 Jul; 83(7):1006-10.